Nondividing cancer cells are relatively resistant to chemotherapeutic drugs and environmental stress factors. Promoting cell cycle re-entry of quiescent cancer cells is a potential strategy to enhance the cytotoxicity of agents that target cycling cells. It is therefore important to elucidate the mechanisms by which these cells are maintained in the quiescent state. The protein kinase dual specificity tyrosine phosphorylation-regulated kinase 1B (DYRK1B) is overexpressed in a subset of cancers and maintains cellular quiescence by counteracting G 0 /G 1 -S phase transition. Specifically, DYRK1B controls the S phase checkpoint by stabilizing the cyclin-dependent kinase (CDK) inhibitor p27
Introduction
The ability to sustain chronic proliferation is a fundamental trait of cancer cells. Conventional chemotherapy strategies target rapidly dividing cells, e.g., by inhibiting critical steps of cell division (mitosis, DNA synthesis) or by exploiting the increased vulnerability of cycling cells to genotoxic or metabolic stress. Similarly, most mechanism-based anticancer drugs such as tyrosine kinase inhibitors interfere with signaling pathways that drive cancer cell proliferation. However, microenvironmental conditions such as crowding and depletion of critical nutrients and growth factors limit cancer cell proliferation and result in cell cycle exit. Thus, a substantial fraction of cancer cells remains in a reversible, nondividing state called quiescence that renders them relatively resistant to chemotherapy [1, 2] . Preventing cell cycle exit and promoting cell cycle reentry of quiescent cells is a potential strategy for sensitizing cancer cells to anticancer drugs. It is therefore important to decipher the mechanisms that regulate cancer cell quiescence.
The protein kinase dual specificity tyrosine phosphorylation-regulated kinase 1B (DYRK1B) has emerged as a druggable protein that regulates G 0 /G 1 -S phase transition. This review summarizes current evidence that a subset of cancer cells depends on active DYRK1B to maintain the quiescent state and contemplates the potential therapeutic approach to overcome chemoresistance of quiescent cancer cells by pharmacological inhibition of DYRK1B.
DYRKs are negative regulators of growth
The first member of the DYRK family of protein kinases has been identified in yeast, where YAK1 is a negative regulator of growth [3] . YAK1 is upregulated by starvation and supports survival of quiescent cells by adapting metabolism and coordinating stress responses. Thus, YAK1 reprograms gene expression to increase energy storage, reduce ribosome biogenesis, upregulate the antioxidant defense system, and enhance thermotolerance [4] . This phenotype is strikingly similar to quiescence in mammalian cells [2] .
Five members of the DYRK family exist in humans, including the paralogous DYRK1A and DYRK1B which share high sequence similarity in the catalytic domain ( Fig. 1) [5, 6] . These kinases have partially overlapping functions but differ in their expression pattern and subcellular localization. DYRK1B was independently discovered as a protein that is overexpressed in a subset of colon carcinomas and mediates tumor cell survival in mitogen-poor environments [7] . Pioneering work by the Friedman group (who termed the protein "Mirk") has revealed two key functions of DYRK1B that contribute to cancer cell chemoresistance: First, DYRK1B functions as a checkpoint kinase that controls the switch from a noncycling G 0 state to S phase. Second, DYRK1B counteracts oxidative stress by reducing intracellular levels of reactive oxygen species (ROS) through the upregulation of antioxidant genes.
Cell cycle function of DYRK1B
DYRK1B levels are highly increased in nondividing cells such as serum-starved fibroblasts and myoblasts that exit cell cycle to undergo terminal differentiation [8] . Very recently, DYRK1B levels were also found to be strongly upregulated in NIH3T3 cells arrested by overexpression of growth arrest-specific 1 (GAS1) [9] . DYRK1B knockdown by RNA interference (RNAi) enables G 0 -arrested NIH-3T3 fibroblasts and C2C12 myoblasts to re-enter the cell cycle, whereas overexpression of DYRK1B results in cell cycle arrest. In addition to skeletal muscle, DYRK1B is highly expressed in testis where it negatively regulates proliferation of immature male germ cells [10] .
Importantly, the same observation has been made in cancer cell lines. DYRK1B levels are strongly upregulated when tumor cells exit the cell cycle upon mitogen deprivation or pharmacological inhibition of proliferative pathways, e.g., in colon carcinoma cells [7, 11] (Fig. 2) .
Multiple mechanisms contribute to the negative regulatory effect of DYRK1B on cell cycle re-entry (Fig. 3) . Phosphorylation by DYRK1B results in the degradation of cyclin D1 and stabilization of p27 Kip1 [18] [19] [20] [21] . Both outcomes counteract the activity of cyclin-dependent kinases (CDKs) that control S phase entry. Notably, DYRK1A has the same effects on cyclin D1 and p27
Kip1 [22, 23] . Furthermore, DYRK1A and DYRK1B have been reported to activate the DREAM (DP, RB, E2F, and MuvB) complex by phosphorylating LIN52 on Ser28 [24] . DREAM is a master coordinator of cell cycle-dependent gene expression and is essential to maintain the noncycling G 0 state [25] . However, cyclin D1 degradation was shown to be the dominant and immediate effect of and DYRK1B share 85% sequence identity in the catalytic domain (cat) and the adjacent N-terminal region which includes the DYRK homology box (DH), a bipartite nuclear localization sequence (NLS), and a binding site for the adaptor protein DCAF7 [65] . The Cterminal regions of both DYRK1A and DYRK1B contain a proline-, glutamic acid-, serine-, threonine-(PEST-) rich region, but show no significant sequence similarity. DYRK1A contains a poly-histidine tract (polyHis) that directs the protein to the nuclear speckle compartment [66] .
DYRK1A in the suppression of S-phase entry, while LIN52 may rather be involved in long-term regulation of cell fate [23] .
The relative contribution of either DYRK1A or DYRK1B to cell cycle regulation appears to depend on the specific experimental system. In aggregate, knockdown experiments suggest that many tumor cell lines with high expression levels of DYRK1B depend on the activity of this kinase to maintain quiescence (see Table 1 ), while DYRK1A has been shown to regulate cell cycle exit in terminal differentiation of neurons and lymphocytes [22, 26, 27] .
Prosurvival function of DYRK1B
In many cancer cell lines, depletion of DYRK1B impairs cell survival and induces apoptosis, concomitant with increased intracellular levels of ROS and phosphorylation of histone 2AX on Ser139, which indicates DNA damage (Table 1 ). DYRK1B upregulates [29] . Targeting the antioxidant capacity of tumor cells and thereby increasing cellular ROS levels has been proposed as a potential strategy for anticancer therapy [30] . Importantly, depletion or inhibition of DYRK1B sensitizes cancer cells to chemotherapeutic drugs that increase ROS levels, such as cisplatin [28, 31] . DYRK1A has been reported to upregulate the expression of the antioxidant NAD(P)H:quinone oxidoreductase-1 (NQO1) [32] , but the effect of DYRK1A on ROS levels in cancer cells has not yet been studied.
Other mechanisms may contribute to the antiapoptotic function of DYRK1B. DYRK1A and DYRK1B mediate nuclear exclusion and thereby inactivation of the forkhead box O (FOXO) transcription factors, FOXO1 and FOXO3A [33, 34] . FOXO factors function as tumor suppressors in a variety of cancers by inhibiting cell proliferation and promoting apoptosis signaling [35] . DYRK1B depletion was shown to enhance nuclear translocation of FOXO1 and FOXO3A and increase apoptosis of ovarian cancer cells [34] .
Other downstream effects of DYRK1B in cancer cells
Both DYRK1A and DYRK1B interact in a complex manner with the oncogenic transcription factor gliomaassociated oncogene family zinc finger 1 (GLI1) and can either promote or block Hedgehog signaling via different pathways [36] [37] [38] [39] [40] [41] . Nevertheless, long-term treatment with the DYRK1 inhibitor, harmine, reduced GLI1 levels in a genetically engineered mouse model of pancreatic cancer, albeit without a clear effect on the disease [38] . In contrast, depletion or inhibition of DYRK1 significantly reduced in vivo tumor growth of GLI1-dependent pancreatic cancer cell lines in xenograft assays [39] . It remains to be clarified whether this effect depends on GLI1 as the critical downstream target of DYRK1B.
In prostate cancer, DYRK1B has been shown to target the tumor suppressor NKX3.1 for proteasomal degradation [42] . Expression of NKX3.1 is consistently reduced in prostatic neoplasia, and loss of NKX3.1 function is considered a critical step in prostate cancer dedifferentiation. Pharmacological inhibition or knockdown of DYRK1B was shown to reduce the turnover of NKX3.1 in the LNCaP prostate cancer cell line [42] . , and formation of the DREAM complex by phosphorylation of the LIN52 subunit of MuvB. DYRK1B supports cell survival by upregulation of antioxidant genes. Phosphorylation by DYRK1B induces the degradation of the prostate cancerspecific tumor suppressor protein NKX3.1, reduces the activity of FOXO transcription factors by nuclear exclusion, and enhances oncogenic GLI1 activity. Oncoproteins supporting proliferation are shown in green, and antiproliferative tumor suppressor proteins in red.
Regulation of DYRK1B
As noted above, the cell cycle function of DYRK1B is strongly regulated by the level of its protein abundance. DYRK1B is always autophosphorylated and catalytically active when isolated from tissues or cells, which is ought to the fact that DYRKs activate themselves irreversibly by tyrosine autophosphorylation during or immediately after translation [43] . Nevertheless, the activity of DYRK1B has been shown to be further enhanced by Rac1-mitogen-activated protein kinase kinase 3 (MKK3) signaling [44] and negatively regulated by binding of Ran-binding protein M (RanBP9) [45] . Furthermore, DYRK1B activity is modestly stimulated through direct phosphorylation of Ser421 by ERK1/2 downstream of the Ras-Raf pathway [21] . In conclusion, the known upstream regulators have limited effects on DYRK1B activity and do not lend themselves to exploitation as drug targets.
Overexpression of DYRK1B in solid tumors and cancer cell lines
In spite of its role as an inhibitor of proliferation, DYRK1B is overexpressed in certain cancer cell lines and in a subset of resected cancer specimens (Table 2) . Amplification of the DYRK1B gene is present in 28 of 995 cancer cell lines that were characterized in the Cancer Cell Line Encyclopedia [46] and in up to 10% of solid tumors, including pancreatic cancer and ovarian cancer (cBioPortal for Cancer Genomics) [47] . For example, DYRK1B was among 16 genes within the minimal subregion of the 19q13 amplicon in pancreatic cancers, including the Panc1 and SU86.86 cells lines [48] . This amplicon contains the putative oncogene AKT2 but has also been proposed to be maintained by selection for DYRK1B [49] . Overexpression of DYRK1B is more frequent than gene amplification, indicating that other mechanisms are involved, such as epigenetic changes. It may appear difficult to reconcile the overexpression of DYRK1B in cancer with its role as a cell cycle inhibitor. However, the survival functions of DYRK1B seem to predominate over its antiproliferative effects and give cancer cells in solid tumors a growth advantage in conditions of increased stress or decreased nutrient and mitogen availability.
Effects of DYRK1B inactivation by RNA interference
The role of DYRK1B in cancer cell growth and survival has been extensively explored with the help of RNAi experiments (Table 1) . Knockdown of DYRK1B expression resulted in reduced numbers of quiescent cells, increased cell cycle entry of G 1 /G 0 cells, reduced clonogenic capacity in colony formation assays, increased DNA damage, and induction of apoptosis in various cell lines. Interestingly, depletion of DYRK1B (but not DYRK1A) also inhibited clonogenic growth of PANC1 cells in three-dimensional (3D) cell cultures, i.e., the formation of multicellular aggregates called spheroids [39] . Spheroid cells are largely quiescent and resistant to chemotherapeutics and express elevated levels of DYRK1B [50] . Primary tumor-derived spheroids are a characteristic feature of epithelial ovarian cancer. Knockdown of either DYRK1A or DYRK1B reduced the viability of nonadherent spheroids from most of 10 ovarian cell lines tested (including primary spheroid cells from patient ascites) much stronger than that of adherent cells that were grown under two-dimensional conditions [51] . Table 2 . Overexpression of DYRK1B in cancer. Immunohistochemistry data on DYRK1B abundance in tumor samples and western blot results from cancer cell lines were taken from the indicated references. Data on DYRK1B gene amplification were extracted from all cancer genomic studies with copy number alteration data that were accessible at cBioPortal.com (accessed on September 12, 2017).
Cancer type Expression of DYRK1B
Amplification of DYRK1B 50, 52, 53] . Thus, a subset of cancer cells seems to have become dependent on the continued activity of overexpressed DYRK1B, a phenomenon called oncogene addiction [54] . Oncogene addiction typically renders cancer cells hypersensitive to drugs that selectively target the respective pathways. This difference in sensitivity suggests that chemotherapy with DYRK1B inhibitors will predominately target the cancer cells themselves, which broadens the therapeutic margin. However, it must be noted that heterozygous missense mutations of DYRK1B cause a rare familiar form of human metabolic syndrome [55] . The pathogenic mutations were shown to impair protein function [56, 57] , suggesting that inhibition of DYRK1B might result in metabolic side effects.
DYRK1A and DYRK1B
The function of DYRK1B in cancer cell quiescence and survival is well supported by the RNAi experiments listed in Table 1 , but it must be stressed that the kinase inhibitors used target both DYRK1A and DYRK1B. A crystal structure of DYRK1B is not yet available, but the high sequence similarity of the catalytic domains (Fig. 1 ) allows the conclusion that the ATP competitive inhibitors can typically form the same contacts with amino acid side chains in both kinases. AZ191 is the only known compound with some degree of selectivity and inhibits DYRK1B with a 5-to 10-fold higher potency over DYRK1A [14, 21] . As noted above, DYRK1A has similar cell cycle functions as DYRK1B, and the inactivation of DYRK1A may contribute to the effects of pharmacological DYRK1 inhibition on cancer cells. The functions of DYRK1A in tumorigenesis and the potential use of DYRK1A inhibitors in cancer therapy have been reviewed before [58, 59] . In fact, DYRK1A was the primary target in two of the studies listed in Table 1 [51, 60] . Nevertheless, inhibition of DYRK1A bears risks of adverse drug reactions, as DYRK1A is a ubiquitously expressed protein with a multitude of functions in the regulation of cellular processes, including neuronal development, synaptic transmission, chromatin remodeling, and alternative mRNA splicing [61] . Moreover, DYRK1A is a model example of a dosage-sensitive gene [62] , implying that even small changes in activity can have severe functional consequences. Cross-reactivity with DYRK1A must therefore be considered a risk factor for unwanted side effects when small molecule drugs are developed to inhibit DYRK1B in cancer cells.
Conclusions and perspectives
Cell culture experiments, including culture of spheroids, as well as xenograft assays provide evidence that DYRK1B inhibitors can promote cell cycle re-entry of quiescent tumor cells and interfere with the cellular antioxidant defense mechanisms.
Future studies must address several pivotal questions to validate DYRK1B inhibitors as a potential therapeutic principle in cancer therapy. Will the cellular effects of DYRK1B inhibition translate to effects on solid tumors in mouse models for spontaneous and induced cancer? Which fraction of tumors from a heterogeneous patient population will be responsive to DYRK1B inhibition? Will the side effects caused by DYRK1A inhibition be acceptable, or is it feasible to develop potent inhibitors that are sufficiently selective for DYRK1B?
Finally, it requires careful attention that cell cycle re-entry of quiescent cancer cells has the potential to elicit relapse and metastasis of dormant tumors [63] . Encouragingly, the phenomenon of oncogene addiction in DYRK1B-overexpressing cell lines suggests that such positively selected cancer cells are dependent on the prosurvival and antioxidant function of DYRK1B. Thus, DYRK1B inhibitors may be most effectively combined with drugs that induce oxidative stress, such
